DelveInsight’s “Severe Hypertriglyceridemia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Severe Hypertriglyceridemia, historical and forecasted epidemiology as well as the Severe Hypertriglyceridemia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Severe Hypertriglyceridemia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Severe Hypertriglyceridemia Market Forecast
Some of the key facts of the Severe Hypertriglyceridemia Market Report:
The Severe Hypertriglyceridemia market size was valued approximately ~USD 2,421 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In March 2024, Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has launched an Expanded Access Program (EAP) to provide investigational plozasiran to eligible patients with familial chylomicronemia syndrome (FCS) outside of clinical trials. Additionally, the company will present final Phase 2 data from the double-blind segment of the SHASTA-2 study, which evaluated plozasiran in patients with severe hypertriglyceridemia.
In 2023, the United States held the largest market share for severe hypertriglyceridemia, comprising about 58% of the total market size in the 7MM, in comparison to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
In 2023, Germany recorded the largest market size for severe hypertriglyceridemia among European countries, reaching approximately USD 180 million, whereas Spain had the smallest market size at around USD 100 million.
In 2023, the market size for severe hypertriglyceridemia in Japan was estimated at approximately USD 324 million, representing 13% of the total market across the 7MM.
The anticipated introduction of new therapies, including ARO-APOC3, is expected to impact the overall market size of severe hypertriglyceridemia in the coming years.
In 2023, the total number of prevalent cases of Hypertriglyceridemia in the 7MM was 155 million, and this figure is anticipated to increase by 2034.
The United States had the highest diagnosed prevalence of Hypertriglyceridemia among the 7MM countries. According to DelveInsight’s estimates, it accounts for approximately 44% of the total diagnosed prevalent cases of hypertriglyceridemia in the 7MM.
In 2023, the diagnosed prevalent cases of Severe Hypertriglyceridemia (SHTG) in the 7MM were approximately 3,495 thousand, with expectations for an increase during the forecast period.
In 2023, Germany reported the highest number of diagnosed prevalent cases of Hypertriglyceridemia among European countries, with approximately 7 million cases, followed by the UK. Conversely, Spain had the lowest prevalence, with around 4 million cases.
In 2023, within the 7MM, severe hypertriglyceridemia cases were classified by etiology. The diagnosed prevalent cases of primary and secondary severe hypertriglyceridemia were approximately 1,500 thousand and 1,980 thousand, respectively.
In 2023, the EU4 and the UK reported approximately 1,388 thousand diagnosed prevalent cases of severe hypertriglyceridemia. Among these, Germany accounted for about 364 thousand cases, representing the highest number of diagnosed prevalent cases of severe hypertriglyceridemia in Europe.
In 2023, Japan represented 16% of the total diagnosed prevalent cases of severe hypertriglyceridemia in the 7MM, with around 562 thousand cases.
Key Severe Hypertriglyceridemia Companies: Amarin Corporation, Ionis Pharmaceuticals, 89bio, Inc., Arrowhead Pharmaceuticals, Inc., Hightide Therapeutics, AstraZeneca, Kowa Research Institute, Inc., Regeneron Pharmaceuticals, Mochida Pharmaceutical, NeuroBo Pharma, Arisaph Pharma, Acasti Pharma Inc., and others
Key Severe Hypertriglyceridemia Therapies: VASCEPA/VAZKEPA, Plozasiran (ARO-APOC3), Olezarsen, Pegozafermin (BIO89-100), ARO-APOC3, HTD1801, omefas, K-877, evinacumab, Ethyl Icosapentate, Gemcabene, ARI-3037MO, CaPre, Epanova, and others
The Severe Hypertriglyceridemia epidemiology based on gender analyzed that the severity‐specific data reveal the highest number of cases were observed in moderate level of HTG
The Severe Hypertriglyceridemia market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Severe Hypertriglyceridemia pipeline products will significantly revolutionize the Severe Hypertriglyceridemia market dynamics.
Severe Hypertriglyceridemia Overview
Primary illnesses and secondary disorders are the two basic categories into which severe hypertriglyceridemia falls. Genetic illnesses fall under the category of main disorders, with secondary causes and other underlying conditions frequently contributing to the latter.
Get a Free sample for the Severe Hypertriglyceridemia Market Report:
https://www.delveinsight.com/report-store/severe-hypertriglyceridemia-shtg-market
Severe Hypertriglyceridemia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Severe Hypertriglyceridemia Epidemiology Segmentation:
The Severe Hypertriglyceridemia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Severe Hypertriglyceridemia
Prevalent Cases of Severe Hypertriglyceridemia by severity
Gender-specific Prevalence of Severe Hypertriglyceridemia
Diagnosed Cases of Episodic and Chronic Severe Hypertriglyceridemia
Download the report to understand which factors are driving Severe Hypertriglyceridemia epidemiology trends @ Severe Hypertriglyceridemia Epidemiology Forecast
Severe Hypertriglyceridemia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Severe Hypertriglyceridemia market or expected to get launched during the study period. The analysis covers Severe Hypertriglyceridemia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Severe Hypertriglyceridemia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Severe Hypertriglyceridemia Therapies and Key Companies
VASCEPA/VAZKEPA: Amarin Corporation
Plozasiran (ARO-APOC3): Arrowhead Pharmaceuticals, Inc.
Olezarsen: Ionis Pharmaceuticals
Pegozafermin (BIO89-100): 89bio, Inc.
ARO-APOC3: Arrowhead Pharmaceuticals, Inc.
HTD1801: HightideTherapeutics
omefas: AstraZeneca
K-877: Kowa Research Institute, Inc.
evinacumab: Regeneron Pharmaceuticals
Ethyl Icosapentate: Mochida Pharmaceutical
Gemcabene: NeuroBo Pharma
ARI-3037MO: Arisaph Pharma
CaPre: Acasti Pharma Inc.
Epanova: AstraZeneca
Discover more about therapies set to grab major Severe Hypertriglyceridemia market share @ Severe Hypertriglyceridemia Treatment Market
Severe Hypertriglyceridemia Market Strengths
The increasing prevalent population and increasing episodes of primary and secondary causes worldwide are likely to cause a surge in treatment options. Consequently, the market will witness a boost in the upcoming year
Severe Hypertriglyceridemia Market Opportunities
Medications with better safety and effectiveness, which provide an optimum cure, are the current unmet need of the SHTG disease market.
Scope of the Severe Hypertriglyceridemia Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Severe Hypertriglyceridemia Therapeutic Assessment: Severe Hypertriglyceridemia current marketed and Severe Hypertriglyceridemia emerging therapies
Severe Hypertriglyceridemia Market Dynamics: Severe Hypertriglyceridemia market drivers and Severe Hypertriglyceridemia market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Severe Hypertriglyceridemia Unmet Needs, KOL’s views, Analyst’s views, Severe Hypertriglyceridemia Market Access and Reimbursement
To know more about Severe Hypertriglyceridemia companies working in the treatment market, visit @ Severe Hypertriglyceridemia Clinical Trials and Therapeutic Assessment
Table of Contents
1. Severe Hypertriglyceridemia Market Report Introduction
2. Executive Summary for Severe Hypertriglyceridemia
3. SWOT analysis of Severe Hypertriglyceridemia
4. Severe Hypertriglyceridemia Patient Share (%) Overview at a Glance
5. Severe Hypertriglyceridemia Market Overview at a Glance
6. Severe Hypertriglyceridemia Disease Background and Overview
7. Severe Hypertriglyceridemia Epidemiology and Patient Population
8. Country-Specific Patient Population of Severe Hypertriglyceridemia
9. Severe Hypertriglyceridemia Current Treatment and Medical Practices
10. Severe Hypertriglyceridemia Unmet Needs
11. Severe Hypertriglyceridemia Emerging Therapies
12. Severe Hypertriglyceridemia Market Outlook
13. Country-Wise Severe Hypertriglyceridemia Market Analysis (2020–2034)
14. Severe Hypertriglyceridemia Market Access and Reimbursement of Therapies
15. Severe Hypertriglyceridemia Market Drivers
16. Severe Hypertriglyceridemia Market Barriers
17. Severe Hypertriglyceridemia Appendix
18. Severe Hypertriglyceridemia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
